Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial

por Kurokawa, Y, Boku, N, Yamaguchi, T, Ohtsu, A, Mizusawa, J, Nakamura, K, Fukuda, H
Publicado 2016

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

por Doi, T, Ohtsu, A, Yoshino, T, Boku, N, Onozawa, Y, Fukutomi, A, Hironaka, S, Koizumi, W, Sasaki, T
Publicado 2012

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

por Koizumi, W, Tanabe, S, Saigenji, K, Ohtsu, A, Boku, N, Nagashima, F, Shirao, K, Matsumura, Y, Gotoh, M
Publicado 2003

Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer

por Katakami, N, Harada, T, Murata, T, Shinozaki, K, Tsutsumi, M, Yokota, T, Arai, M, Tada, Y, Narabayashi, M, Boku, N
Publicado 2018

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer

por Koizumi, W., Boku, N., Yamaguchi, K., Miyata, Y., Sawaki, A., Kato, T., Toh, Y., Hyodo, I., Nishina, T., Furuhata, T., Miyashita, K., Okada, Y.
Publicado 2010

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

por Okamoto, W., Sakai, K., Makiyama, A., Yamamoto, Y., Shitara, K., Denda, T., Izawa, N., Nakano, Y., Nishina, T., Esaki, T., Hara, H., Miura, Y., Boku, N., Yamazaki, K., Hironaka, S., Misumi, T., Hyodo, I., Muro, K., Nishio, K.
Publicado 2022

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroeso...

por Boku, N, Ryu, M -H, Kato, K, Chung, H C, Minashi, K, Lee, K -W, Cho, H, Kang, W K, Komatsu, Y, Tsuda, M, Yamaguchi, K, Hara, H, Fumita, S, Azuma, M, Chen, L -T, Kang, Y -K
Publicado 2019

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

por Mochizuki, I, Takiuchi, H, Ikejiri, K, Nakamoto, Y, Kinugasa, Y, Takagane, A, Endo, T, Shinozaki, H, Takii, Y, Takahashi, Y, Mochizuki, H, Kotake, K, Kameoka, S, Takahashi, K, Watanabe, T, Watanabe, M, Boku, N, Tomita, N, Matsubara, Y, Sugihara, K
Publicado 2012

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)

por Yoshida, M., Ishiguro, M., Ikejiri, K., Mochizuki, I., Nakamoto, Y., Kinugasa, Y., Takagane, A., Endo, T., Shinozaki, H., Takii, Y., Mochizuki, H., Kotake, K., Kameoka, S., Takahashi, K., Watanabe, T., Watanabe, M., Boku, N., Tomita, N., Nakatani, E., Sugihara, K.
Publicado 2014

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)

por Ueno, M., Okusaka, T., Omuro, Y., Isayama, H., Fukutomi, A., Ikeda, M., Mizuno, N., Fukuzawa, K., Furukawa, M., Iguchi, H., Sugimori, K., Furuse, J., Shimada, K., Ioka, T., Nakamori, S., Baba, H., Komatsu, Y., Takeuchi, M., Hyodo, I., Boku, N.
Publicado 2016

S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the p...

por Watanabe, J., Sasaki, S., Kusumoto, T., Sakamoto, Y., Yoshida, K., Tomita, N., Maeda, A., Teshima, J., Yokota, M., Tanaka, C., Yamauchi, J., Uetake, H., Itabashi, M., Takahashi, K., Baba, H., Kotake, K., Boku, N., Aiba, K., Morita, S., Takenaka, N., Sugihara, K.
Publicado 2021

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

por Okusaka, Takuji, Miyakawa, H., Fujii, H., Nakamori, S., Satoh, T., Hamamoto, Y., Ito, T., Maguchi, H., Matsumoto, S., Ueno, H., Ioka, T., Boku, N., Egawa, S., Hatori, T., Furuse, J., Mizumoto, K., Ohkawa, S., Yamaguchi, T., Yamao, K., Funakoshi, A., Chen, J. S., Cheng, A. L., Sato, A., Ohashi, Y., Tanaka, M.
Publicado 2017

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: p...

por Bang, Y -J, Ruiz, E Yañez, Van Cutsem, E, Lee, K -W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M -H, Chung, H -C, Evesque, L, Al-Batran, S -E, Park, S H, Lichinitser, M, Boku, N, Moehler, M H, Hong, J, Xiong, H, Hallwachs, R, Conti, I, Taieb, J
Publicado 2018